About
ORCA Therapeutics develops oncolytic virus-based immunotherapies targeting prostate cancer, with its lead candidate ORCA-010 currently in Phase I/IIa clinical trials in treatment-naive patients with localized prostate cancer in Canada.
Explore ORCA Therapeutics B.V.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.